The state of Indiana used a $2 million grant to lure PDS Biotechnology, a Cincinnati-based company developing nanoparticle treatments for the immune system that could prevent cancer, HPV and several other kinds of infections, according to a press release.
Indiana used money from its 21st Century Research and Technology fund.
PDS had operated in the BioStart incubator in Cincinnati, so it has received some services through the state. But PDS had never receive state funding through Third Frontier or other programs, said Matt Schutte of BioOhio. Three months ago, the U.S. National Cancer Institute’s Nanotechnology Characterization Lab announced it would work with PDS to complete preclinical development of its HPV-cancer therapy.
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.